CEP55 and glioblastoma: Collectively, six tumors, namely, GBM, PRAD, UCEC, COAD, STAD, and KIRC, demonstrated a positive correlation between CEP55 and both TMB and MSI; thus, CEP55 can be used as a biomarker for the response of the patients of these tumors to immune checkpoint inhibitors.